Molecular pathogenesis and early detection of hepatocellular carcinoma - Perspectives from West Africa

Cancer Letters

Volumn 286, Issue 1, 2009, Pages 44-51

  Mendy, Maimuna ^a   Walton, Robert ^b  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Early detection; Hepatocellular carcinoma; Molecular pathogenesis

Indexed keywords

AFLATOXIN B1; BIOLOGICAL MARKER;

AFRICA; CANCER DIAGNOSIS; CANCER SURVIVAL; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; GENDER; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HOST; HUMAN; INNATE IMMUNITY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SHORT SURVEY;

EID: 70350767515     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.04.039     Document Type: Review

References (95)

1. Viviani S., Carrieri P., Bah E., Hall A.J., Kirk G.D., Mendy M., Montesano R., Plymoth A., Sam O., Van der Sande M., Whittle H., and Hainaut P. 20 years into the Gambia hepatitis intervention study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol. Biomarkers Prev. 17 (2008) 3216-3223
2. Turner P.C., Sylla A., Gong Y.Y., Diallo M.S., Sutcliffe A.E., Hall A.J., and Wild C.P. Reduction in exposure to carcinogenic aflatoxins by postharvest intervention measures in West Africa: a community-based intervention study. Lancet 365 (2005) 1950-1956
3. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55 (2005) 74-108
4. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
5. Beasley R.P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 61 (1988) 1942-1956
6. Yano M., Yatsuhashi H., Inoue O., Inokuchi K., and Koga M. Epidemiology and long term prognosis of hepatitis C virus infection in Japan. Gut 34 (1993) S13-S16
7. Kirk G.D., Turner P.C., Gong Y., Lesi O.A., Mendy M., Goedert J.J., Hall A.J., Whittle H., Hainaut P., Montesano R., and Wild C.P. Hepatocellular carcinoma and polymorphisms in carcinogen-metabolizing and DNA repair enzymes in a population with aflatoxin exposure and hepatitis B virus endemicity. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 373-379
8. Donato F., Boffetta P., and Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int. J. Cancer 75 (1998) 347-354
9. Shi J., Zhu L., Liu S., and Xie W.F. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br. J. Cancer 92 (2005) 607-612
10. Smela M.E., Currier S.S., Bailey E.A., and Essigmann J.M. The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis. Carcinogenesis 22 (2001) 535-545
11. Bressac B., Kew M., Wands J., and Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from Southern Africa. Nature 350 (1991) 429-431
12. Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F., Fujii S., Arlinghaus R.B., Czerniak B.A., and Sen S. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat. Genet. 36 (2004) 55-62
13. Kirk G.D., Lesi O.A., Mendy M., Szymanska K., Whittle H., Goedert J.J., Hainaut P., and Montesano R. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene 24 (2005) 5858-5867
14. Montesano R., Hainaut P., and Wild C.P. Hepatocellular carcinoma: from gene to public health. J. Natl. Cancer Inst. 89 (1997) 1844-1851
15. Sylla A., Diallo M.S., Castegnaro J., and Wild C.P. Interactions between hepatitis B virus infection and exposure to aflatoxins in the development of hepatocellular carcinoma: a molecular epidemiological approach. Mutat. Res. 428 (1999) 187-196
16. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., and Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317 (2007) 121-124
17. Di Maio M., Daniele B., Pignata S., Gallo C., De Maio E., Morabito A., Piccirillo M.C., and Perrone F. Is human hepatocellular carcinoma a hormone-responsive tumor?. World J. Gastroenterol. 14 (2008) 1682-1689
18. Jie X., Lang C., Jian Q., Chaoqun L., Dehua Y., Yi S., Yanping J., Luokun X., Qiuping Z., Hui W., Feili G., Boquan J., Youxin J., and Jinquan T. Androgen activates PEG10 to promote carcinogenesis in hepatic cancer cells. Oncogene 26 (2007) 5741-5751
19. Chiu C.M., Yeh S.H., Chen P.J., Kuo T.J., Chang C.J., Yang W.J., and Chen D.S. Hepatitis B virus X protein enhances androgen receptor-responsive gene expression depending on androgen level. Proc. Natl. Acad. Sci. USA 104 (2007) 2571-2578
20. D'Amico F., Biancolella M., Margiotti K., Reichardt J.K., and Novelli G. Genomic biomarkers, androgen pathway and prostate cancer. Pharmacogenomics 8 (2007) 645-661
21. Westin J., Lagging L.M., Wejstal R., Norkrans G., and Dhillon A.P. Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver 19 (1999) 183-187
22. Bedossa P., Dargere D., and Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38 (2003) 1449-1457
23. Alpert M.E., Uriel J., and de Nechaud B. Alpha-1 fetoglobulin in the diagnosis of human hepatoma. N. Engl. J. Med. 278 (1968) 984-986
24. Takashima T., Matsui O., Suzuki M., and Ida M. Diagnosis and screening of small hepatocellular carcinomas. Comparison of radionuclide imaging, ultrasound, computed tomography, hepatic angiography, and alpha 1-fetoprotein assay. Radiology 145 (1982) 635-638
25. Taketa K. Alpha-fetoprotein: reevaluation in hepatology. Hepatology 12 (1990) 1420-1432
26. Soresi M., Magliarisi C., Campagna P., Leto G., Bonfissuto G., Riili A., Carroccio A., Sesti R., Tripi S., and Montalto G. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res. 23 (2003) 1747-1753
27. Spangenberg H.C., Lee H.B., Li J., Tan F., Skidgel R., Wands J.R., and Tong S. A short sequence within domain C of duck carboxypeptidase D is critical for duck hepatitis B virus binding and determines host specificity. J. Virol. 75 (2001) 10630-10642 (JID - 0113724)
28. Mendy M., Kirk G.D., van der Sande M., Jeng-Barry A., Lesi O.A., Hainaut P., Sam O., McConkey S., and Whittle H. Hepatitis B surface antigenaemia and alpha-foetoprotein detection from dried blood spots: applications to field-based studies and to clinical care in hepatitis B virus endemic areas. J. Viral Hepat. 12 (2005) 642-647
29. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 34 (2001) 1225-1241
30. Marrero J.A. Hepatocellular carcinoma. Curr. Opin. Gastroenterol. 22 (2006) 248-253
31. Marrero J.A. Screening tests for hepatocellular carcinoma. Clin. Liver Dis. 9 (2005) 235-251 vi
32. Paterson A.C., Kew M.C., Herman A.A., Becker P.J., Hodkinson J., and Isaacson C. Liver morphology in Southern African blacks with hepatocellular carcinoma: a study within the urban environment. Hepatology 5 (1985) 72-78
33. Kew M.C. Clinical, pathologic, and etiologic heterogeneity in hepatocellular carcinoma: evidence from Southern Africa. Hepatology 1 (1981) 366-369
34. Mendy M.E., McConkey S.J., Sande van der M.A., Crozier S., Kaye S., Jeffries D., Hall A.J., and Whittle H.C. Changes in viral load and HBsAg and HBeAg status with age in HBV chronic carriers in The Gambia. Virol. J. 5 (2008) 49
35. Chang M.H., Hsu H.Y., Hsu H.C., Ni Y.H., Chen J.S., and Chen D.S. The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age. Hepatology 22 (1995) 1387-1392
36. Attia K.A., Ackoundou-N'guessan C., N'Dri-Yoman K.A.T., Mahassadi A.K., Messou E., Bathaix Y.F., and Kissi Y.H. Child-Pugh-Turcott versus Meld score for predicting survival in a retrospective cohort of black African cirrhotic patients. World J. Gastroenterol. 14 (2008) 286-291
37. Lesi O.A., Kehinde M.O., and Anomneze E.E. Chronic liver disease in Lagos: a clinicopathological study. Niger. Postgrad. Med. J. 11 (2004) 91-96
38. Poynard T., Imbert-Bismut F., Munteanu M., Messous D., Myers R.P., Thabut D., Ratziu V., Mercadier A., Benhamou Y., and Hainque B. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp. Hepatol. 3 (2004) 8
39. Ngo Y., Munteanu M., Messous D., Charlotte F., Imbert-Bismut F., Thabut D., Lebray P., Thibault V., Benhamou Y., Moussalli J., Ratziu V., and Poynard T. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin. Chem. 52 (2006) 1887-1896
40. Carvalho-Filho R.J., Schiavon L.L., Narciso-Schiavon J.L., Sampaio J.P., Lanzoni V.P., Ferraz M.L., and Silva A.E. Optimized cutoffs improve performance of the aspartate aminotransferase to platelet ratio index for predicting significant liver fibrosis in human immunodeficiency virus/hepatitis C virus co-infection. Liver Int. 28 (2008) 486-493
41. Wai C.T., Greenson J.K., Fontana R.J., Kalbfleisch J.D., Marrero J.A., Conjeevaram H.S., and Lok A.S. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38 (2003) 518-526
42. Block T.M., Mehta A.S., Fimmel C.J., and Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 22 (2003) 5093-5107
43. Magnius L.O., and Norder H. Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology 38 (1995) 24-34 (Review, 57 refs)
44. Stuyver L., De Gendt S., Van Geyt C., Zoulim F., Fried M., Schinazi R.F., and Rossau R. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J. Gen. Virol. 81 Pt 1 (2000) 67-74
45. Kramvis A., Kew M., and Francois G. Hepatitis B virus genotypes. Vaccine 23 (2005) 2409-2423
46. Lindh M., Andersson A.S., and Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus - large-scale analysis using a new genotyping method. J. Infect. Dis. 175 (1997) 1285-1293 (JID - 0413675)
47. Dumpis U., Holmes E.C., Mendy M., Hill A., Thursz M., Hall A., Whittle H., and Karayiannis P. Transmission of hepatitis B virus infection in Gambian families revealed by phylogenetic analysis. J. Hepatol. 35 (2001) 99-104
48. Dai C.Y., Yu M.L., Chuang W.L., Lu S.N., Wang J.H., Huang J.F., Hou C., Chen S.C., Lin Z.Y., Hsieh M.Y., Wang L.Y., Tsai J.F., and Chang W.Y. The epidemiology of TT virus (TTV) infection in a hepatitis C and B virus hyperendemic area of Southern Taiwan. Kaohsiung J. Med. Sci. 16 (2000) 500-509
49. Amini-Bavil-Olyaee S., Sarrami-Forooshani R., Mahboudi F., Sabahi F., Adeli A., Noorinayer B., Azizi M., and Reza Zali M. Genotype characterization and phylogenetic analysis of hepatitis B virus isolates from Iranian patients. J. Med. Virol. 75 (2005) 227-234
50. Kramvis A., Kew M.C., and Bukofzer S. Hepatitis B virus precore mutants in serum and liver of Southern African Blacks with hepatocellular carcinoma. J. Hepatol. 28 (1998) 132-1341
51. Liu C.J., Chen B.F., Chen P.J., Lai M.Y., Huang W.L., Kao J.H., and Chen D.S. Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. J. Infect. Dis. 194 (2006) 594-599
52. Fang Z.L., Sabin C.A., Dong B.Q., Ge L.Y., Wei S.C., Chen Q.Y., Fang K.X., Yang J.Y., Wang X.Y., Harrison T.J., and A1762T H.B.V. G1764A mutations are a valuable biomarker for identifying a subset of male HBsAg carriers at extremely high risk of hepatocellular carcinoma: a prospective study. Am. J. Gastroenterol. 103 (2008) 2254-2262
53. Mendy M.E., Kaye S., Le Roux E., Kirk G.D., Jeng-Barry A., McConkey S., Cotten M., Kuniholm M.H., Leligdowicz A., Hainaut P., Rowland-Jones S., and Whittle H. Rowland-Jones, and H. Whittle, Application of a novel, rapid, and sensitive oligonucleotide ligation assay for detection of cancer-predicting mutations in the precore and basal core promoter of hepatitis B virus. J. Clin. Microbiol. 46 (2008) 2723-2730
54. Lin C.L., and Kao J.H. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J. Biomed. Sci. 15 (2008) 137-145
55. Baumert T.F., Thimme R., and von Weizsacker F. Pathogenesis of hepatitis B virus infection. World J. Gastroenterol. 13 (2007) 82-90
56. Madhava V., Burgess C., and Drucker E. Epidemiology of chronic hepatitis C virus infection in Sub-Saharan Africa. Lancet Infect. Dis. 2 (2002) 293-302
57. Kirk G.D., Lesi O.A., Mendy M., Akano A.O., Sam O., Goedert J.J., Hainaut P., Hall A.J., Whittle H., and Montesano R. The Gambia liver cancer study: infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology 39 (2004) 211-219
58. Wild C.P., Yin F., Turner P.C., Chemin I., Chapot B., Mendy M., Whittle H., Kirk G.D., and Hall A.J. Environmental and genetic determinants of aflatoxin-albumin adducts in The Gambia. Int. J. Cancer 86 (2000) 1-7
59. Ganem D., and Prince A.M. Hepatitis B virus infection - natural history and clinical consequences. N. Engl. J. Med. 350 (2004) 1118-1129
60. Wright T.L. Introduction to chronic hepatitis B infection. Am. J. Gastroenterol. 101 Suppl. 1 (2006) S1-S6
61. Pang R.W., Joh J.W., Johnson P.J., Monden M., Pawlik T.M., and Poon R.T. Biology of hepatocellular carcinoma. Ann. Surg. Oncol. 15 (2008) 962-971
62. Beneduce L., Castaldi F., Marino M., Tono N., Gatta A., Pontisso P., and Fassina G. Improvement of liver cancer detection with simultaneous assessment of circulating levels of free alpha-fetoprotein (AFP) and AFP-IgM complexes. Int. J. Biol. Markers 19 (2004) 155-159
63. Khien V.V., Mao H.V., Chinh T.T., Ha P.T., Bang M.H., Lac B.V., Hop T.V., Tuan N.A., Don L.V., Taketa K., and Satomura S. Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carcinoma. Int. J. Biol. Markers 16 (2001) 105-111
64. Beneduce L., Castaldi F., Marino M., Quarta S., Ruvoletto M., Benvegnu L., Calabrese F., Gatta A., Pontisso P., and Fassina G. Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma. Cancer 103 (2005) 2558-2565
65. Giannelli G., Marinosci F., Trerotoli P., Volpe A., Quaranta M., Dentico P., and Antonaci S. SCCA antigen combined with alpha-fetoprotein as serologic markers of HCC. Int. J. Cancer 117 (2005) 506-509
66. Saitoh S., Ikeda K., Koida I., Tsubota A., Arase Y., Chayama K., and Kumada H. Small hepatocellular carcinoma: evaluation of portal blood flow with CT during arterial portography performed with balloon occlusion of the hepatic artery. Radiology 193 (1994) 67-70
67. Luo J.H., Ren B., Keryanov S., Tseng G.C., Rao U.N., Monga S.P., Strom S., Demetris A.J., Nalesnik M., Yu Y.P., Ranganathan S., and Michalopoulos G.K. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology 44 (2006) 1012-1024
68. Zhu Z.W., Friess H., Wang L., Abou-Shady M., Zimmermann A., Lander A.D., Korc M., Kleeff J., and Buchler M.W. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 48 (2001) 558-564
69. Man X.B., Tang L., Zhang B.H., Li S.J., Qiu X.H., Wu M.C., and Wang H.Y. Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers. Liver Int. 25 (2005) 962-966
70. 2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res. 64 (2004) 2418-2423
71. Blobe G.C., Schiemann W.P., and Lodish H.F. Role of transforming growth factor beta in human disease. N. Engl. J. Med. 342 (2000) 1350-1358
72. Wouters B.G. Proteomics: methodologies and applications in oncology. Semin. Radiat. Oncol. 18 (2008) 115-125
73. Clarke W., Zhang Z., and Chan D.W. The application of clinical proteomics to cancer and other diseases. Clin. Chem. Lab. Med. 41 (2003) 1562-1570
74. Poon T.C., Hui A.Y., Chan H.L., Ang I.L., Chow S.M., Wong N., and Sung J.J. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin. Chem. 51 (2005) 328-335
75. Poon T.C., Yip T.T., Chan A.T., Yip C., Yip V., Mok T.S., Lee C.C., Leung T.W., Ho S.K., and Johnson P.J. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin. Chem. 49 (2003) 752-760
76. Ljunggren H.G., and Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol. Today 11 (1990) 237-244
77. Carrington M., and Martin M.P. The impact of variation at the KIR gene cluster on human disease. Curr. Top Microbiol. Immunol. 298 (2006) 225-257
78. Chen Y., Cheng M., and Tian Z. Hepatitis B virus down-regulates expressions of MHC class I molecules on hepatoplastoma cell line. Cell. Mol. Immunol. 3 (2006) 373-378
79. Taketomi A., Shimada M., Shirabe K., Kajiyama K., Gion T., and Sugimachi K. Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy. Cancer 83 (1998) 58-63
80. Chuang W.L., Liu H.W., and Chang W.Y. Natural killer cell activity in patients with hepatocellular carcinoma relative to early development and tumor invasion. Cancer 65 (1990) 926-930
81. Butsch Kovacic M., Martin M., Gao X., Fuksenko T., Chen C.J., Cheng Y.J., Chen J.Y., Apple R., Hildesheim A., and Carrington M. Variation of the killer cell immunoglobulin-like receptors and HLA-C genes in nasopharyngeal carcinoma. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 2673-2677
82. Carrington M., Wang S., Martin M.P., Gao X., Schiffman M., Cheng J., Herrero R., Rodriguez A.C., Kurman R., Mortel R., Schwartz P., Glass A., and Hildesheim A. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J. Exp. Med. 201 (2005) 1069-1075
83. Lopez-Vazquez A., Rodrigo L., Martinez-Borra J., Perez R., Rodriguez M., Fdez-Morera J.L., Fuentes D., Rodriguez-Rodero S., Gonzaez S., and Lopez-Larrea C. Protective effect of the HLA-Bw4I80 epitope and the killer cell immunoglobulin-like receptor 3DS1 gene against the development of hepatocellular carcinoma in patients with hepatitis C virus infection. J. Infect. Dis. 192 (2005) 162-165
84. Lopez-Vazquez A., Rodrigo L., and Lopez-Larrea C. Association of killer immunoglobulin-like receptors and their HLA Class I ligands with progression of chronic hepatitis C virus infection. Tissue Antigens 69 Suppl. 1 (2007) 241-242
85. Martin M.P., and Carrington M. Immunogenetics of viral infections. Curr. Opin. Immunol. 17 (2005) 510-516
86. Qi Y., Martin M.P., Gao X., Jacobson L., Goedert J.J., Buchbinder S., Kirk G.D., O'Brien S.J., Trowsdale J., and Carrington M. KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathog 2 (2006) e79
87. Hansasuta P., Dong T., Thananchai H., Weekes M., Willberg C., Aldemir H., Rowland-Jones S., and Braud V.M. Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur. J. Immunol. 34 (2004) 1673-1679
88. Thananchai H., Gillespie G., Martin M.P., Bashirova A., Yawata N., Yawata M., Easterbrook P., McVicar D.W., Maenaka K., Parham P., Carrington M., Dong T., and Rowland-Jones S. Cutting edge: allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J. Immunol. 178 (2007) 33-37
89. Gillespie G.M., Bashirova A., Dong T., McVicar D.W., Rowland-Jones S.L., and Carrington M. Lack of KIR3DS1 binding to MHC class I Bw4 tetramers in complex with CD8+ T cell epitopes. AIDS Res. Hum. Retroviruses 23 (2007) 451-455
90. Zhi-ming L., Yu-lian J., Zhao-lei F., Chun-xiao W., Zhen-fang D., Bing-chang Z., and Yue-ran Z. Polymorphisms of killer cell immunoglobulin-like receptor gene: possible association with susceptibility to or clearance of hepatitis B virus infection in Chinese Han population. Croat. Med. J. 48 (2007) 800-806
91. Cui R., He J., Zhang F., Wang B., Ding H., Shen H., Li Y., and Chen X. Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein. Br. J. Cancer 88 (2003) 1878-1882
92. Marrero J.A., and Lok A.S. Newer markers for hepatocellular carcinoma. Gastroenterology 127 (2004) S113-S119
93. Tsai J.F., Jeng J.E., Chuang L.Y., Yang M.L., Ho M.S., Chang W.Y., Hsieh M.Y., Lin Z.Y., and Tsai J.H. Clinical evaluation of urinary transforming growth factor-beta1 and serum alpha-fetoprotein as tumour markers of hepatocellular carcinoma. Br. J. Cancer 75 (1997) 1460-1466
94. Thorgeirsson S.S., and Grisham J.W. Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet. 31 (2002) 339-346
95. Laurent-Puig P., and Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene. 25 27 (2006) 3778-3786